Palmitate-induced skeletal muscle insulin resistance does not require NF-κB activation by Hommelberg, Pascal P. H. et al.
RESEARCH ARTICLE
Palmitate-induced skeletal muscle insulin resistance does
not require NF-jB activation
Pascal P. H. Hommelberg • Jogchum Plat • Lauren M. Sparks •
Annemie M. W. J. Schols • Anon L. M. van Essen • Marco C. J. M. Kelders •
Denis van Beurden • Ronald P. Mensink • Ramon C. J. Langen
Received: 8 April 2010/Revised: 16 July 2010/Accepted: 17 August 2010/Published online: 5 September 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Palmitate activates the NF-jB pathway, and
induces accumulation of lipid metabolites and insulin
resistance in skeletal muscle cells. Little information is
available whether and how these processes are causally
related. Therefore, the objectives were to investigate
whether intra-cellular lipid metabolites are involved in
FA-induced NF-jB activation and/or insulin resistance in
skeletal muscle and to investigate whether FA-induced
insulin resistance and NF-jB activation are causally related.
Inhibiting DGAT or CPT-1 by using, respectively, amidep-
sine or etomoxir increased DAG accumulation and
sensitized myotubes to palmitate-induced insulin resistance.
While co-incubation of palmitate with etomoxir increased
NF-jB transactivation, co-incubation with amidepsine did
not, indicating that DAG accumulation is associated
with insulin resistance but not with NF-jB activation.
Furthermore, pharmacological or genetic inhibition of the
NF-jBpathwaycouldnotpreventpalmitate-inducedinsulin
resistance. In conclusion, we have demonstrated that acti-
vation of the NF-jB pathway is not required for palmitate-
induced insulin resistance in skeletal muscle cells.
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Introduction
Insulin resistance is recognized as an important risk factor
in the development of type 2 diabetes, the prevalence of
which is rapidly increasing [1]. Although it is generally
accepted that this may relate to a Western-type diet high in
saturated fatty acids [2], the detailed pathogenesis under-
lying the initiation of insulin resistance is still poorly
understood. Since skeletal muscle is responsible for
70–80% of insulin-stimulated glucose uptake, skeletal
muscle insulin resistance is most likely a major determi-
nant of type 2 diabetes [3].
Type 2 diabetic patients are characterized by an eleva-
tion in plasma free fatty acids (FFA) [4]. These FFA play a
major role in the pathogenesis of insulin resistance, since
lowering FFA levels in the plasma signiﬁcantly improves
insulin sensitivity [5, 6], whereas lipid infusion leading to
increased plasma FFA induces skeletal muscle insulin
resistance in rodents and humans [7–9]. It is thought that
circulating FFA interfere with insulin signaling as a con-
sequence of cellular FA oversupply or impaired
mitochondrial FA oxidation, leading to intra-muscular
accumulation of FA metabolites. Increased levels of the
lipid metabolite diacylglycerol (DAG) in skeletal muscle
indeed accompanies diet-induced insulin resistance in
Electronic supplementary material The online version of this
article (doi:10.1007/s00018-010-0515-3) contains supplementary
material, which is available to authorized users.
P. P. H. Hommelberg  J. Plat  L. M. Sparks 
D. van Beurden  R. P. Mensink
Department of Human Biology,
Nutrim School for Nutrition,
Toxicology and Metabolism,
Maastricht University Medical Centre,
Maastricht, The Netherlands
A. M. W. J. Schols  A. L. M. van Essen 
M. C. J. M. Kelders  R. C. J. Langen (&)
Department of Respiratory Medicine, Nutrim School
for Nutrition, Toxicology and Metabolism,
Maastricht University Medical Centre,
P.O. Box 616, 6200 MD Maastricht, The Netherlands
e-mail: r.langen@pul.unimaas.nl
P. P. H. Hommelberg  R. P. Mensink
Top Institute Food and Nutrition, Wageningen, The Netherlands
Cell. Mol. Life Sci. (2011) 68:1215–1225
DOI 10.1007/s00018-010-0515-3 Cellular and Molecular Life Sciencesrodents [10] and lipid infusion-induced insulin resistance in
humans [8]. Whether DAG is the crucial trigger and via
which cellular processes DAG accumulation leads to
insulin resistance is still unclear. However, since DAG
accumulation during lipid infusion coincides with nuclear
factor kappa B (NF-jB) activation in insulin-resistant
muscle, NF-jB has been implicated in the mechanism
underlying FA-induced DAG-mediated muscular insulin
resistance [8]. Although several in vitro studies in skeletal
muscle provide evidence that long-chain saturated FA-
induced insulin resistance coincides with DAG accumula-
tion [11] and activation of the NF-jB pathway [12–14],
little information is available if and how these processes
are causally related. Therefore, the ﬁrst objective of this
study was to investigate whether DAG accumulation is
involved in NF-jB activation and/or FA-induced insulin
resistance in skeletal muscle by interfering with b-oxida-
tion and DAG to TAG conversion.
Several studies in rodents and humans showed that
insulin resistance induced by hyperlipidemia (lipid infu-
sion) or an obesity-inducing high fat diet was associated
with decreased IjBa protein levels in skeletal muscle,
which is suggestive for NF-jB activation [8, 15, 16].
Furthermore, whole body inhibition of NF-jB activity by
pharmacological means or by heterozygous deletion of the
NF-jB-activating kinase IKK-2, prevented lipid infusion-,
obesity- and diet-induced insulin resistance [17, 18],
illustrating an important role for NF-jB in whole body
glucose homeostasis.
However, the speciﬁc contribution of NF-jB activation
in skeletal muscle was not assessed in these studies. Mice
with a muscle-speciﬁc inhibition of NF-jB by transgenic
expression of the IjBa super-repressor (MISR mice) were
not protected against the development of diet-induced
whole body insulin resistance [19], and muscle-speciﬁc
IKK-2 deﬁcient mice showed no differences in whole body
glucose homeostasis after gold thioglucose-induced obesity
[20]. Since insulin resistance of other tissues could poten-
tially mask a protective effect of NF-jB inhibition on
muscle glucose homeostasis, in this respect, studies using
cultured muscle cells are of great advantage. In L6 myo-
tubes, it has been shown that palmitate-induced insulin
resistance could be prevented by pharmacological inhibi-
tors of IKK and NF-jB nuclear translocation in L6
myotubes [21, 22]. In contrast, non-saturated FA-induced
NF-jB activation in absence of insulin resistance has been
described in skeletal muscle [23]. Moreover, several stud-
ies showed that stimulation of muscle cells with TNF-a,a
well-known and potent NF-jB activator, does not induce
insulin resistance [24–26], while others showed that mus-
cle-speciﬁc transgenic expression of activated IKK in mice
(MIKK mice) [19] and over-expression of IKK-2 and p65
via in vivo electrotransfer in rat muscles does not induce
insulin resistance [27]. From the latter studies, it appears
that muscular NF-jB activation per se is not sufﬁcient to
induce insulin resistance.
Considering that these conﬂicting results regarding the
requirement of muscular NF-jB activation in FA-induced
insulin resistance may be attributable to differences in
strategies to modulate NF-jB activity, the second objective
of this study was to address the contribution of NF-jB
activation to palmitate-induced insulin resistance in cul-
tured skeletal muscle using both pharmacological and
genetic approaches to inhibit NF-jB activity.
Materials and methods
Cell culture
The C2C12 murine skeletal muscle cell line (ATCC
CRL1772. Manassas, VA), stably transfected with the 6jB-
TK-luciferase, was used for the assessment of NFjB
transcriptional activity. In brief, C2C12 cells were plated
(1 9 10
4 cells/cm
2) on growth factor reduced Matrigel
(Becton–Dickinson Labware, Bedford, MA, USA) coated
(1:50 in Dulbecco’s modiﬁed Eagle’s medium, DMEM)
dishes, as described previously [28]. C2C12 myoblasts
were cultured in growth medium (GM), composed of low
glucose DMEM containing antibiotics (50 U/ml penicillin
and 50 lg/ml streptomycin; both from Gibco-Invitrogen,
Rockville, MD, USA) and 9% (vol/vol) fetal bovine serum
(FBS; PAA Laboratories, UK). To induce differentiation,
GM was replaced by differentiation medium (DM), con-
taining DMEM with 1% (vol/vol) heat-inactivated FBS and
antibiotics. As a positive control for NF-jB transcriptional
activity, murine TNFa (Calbiochem, San Diego, CA, USA)
was added to the dishes.
Myoblasts from the L6 rat skeletal muscle cell line were
cultured in GM, composed of a-MEM (Gibco-Invitrogen)
containing 9% (vol/vol) FBS and antibiotics. The plating
density used for the experiments was 2 9 10
4/cm
2. After
24 h of culturing in growth medium, differentiation was
induced by replacing GM with DM, containing a-MEM
with 2% (vol/vol) heat-inactivated FBS and antibiotics.
Amidepsine A (Alexis, San Diego, CA, USA), etomoxir
and parthenolide (both from Sigma, St. Louis, MO, USA)
were added 30 min before palmitate incubations.
All experiments described for both cell lines were per-
formed in 5- or 6-day differentiated myotubes unless stated
otherwise.
Palmitate incubations
Palmitate (C16:0; Sigma) stock solutions of 40 mmol/l
were prepared in ethanol. Before application to the cells,
1216 P. P. H. Hommelberg et al.palmitate was conjugated to bovine serum albumin (BSA)
by diluting the palmitate solution with differentiation
medium containing 1% (w/v) palmitate-free BSA (Sigma).
Solutions were ﬁlter-sterilized before addition to the cells.
Because of different sensitivities of both cell lines towards
FA-induced NF-jB activation and insulin resistance [12],
maximal palmitate concentrations used are 200 lmol/l for
L6 myotubes and 400 lmol/l for C2C12 myotubes.
Vehicle controls contained equal amounts of ethanol
(max1%inC2C12or0.5%inL6)(v/v)andBSA(1%(w/v)).
Diacylglycerol analysis
Freeze-dried L6 myotubes were extracted overnight at 4C
with chloroform–methanol (2:1 by volume), containing
10 mg/l of butylated hydroxytoluene. After centrifugation,
the supernatant was evaporated under nitrogen gas. Lipids
were reconstituted in chloroform–methanol (1:1), contain-
ing 10 mg/l of butylated hydroxytoluene, spotted onto TLC
plates and developed in a solvent containing petroleum-
benzin-diethyl ether-acetic acid (120:25:1,5 by volume).
The DAG fractions were identiﬁed against a DAG standard
(Sigma) and scraped into a vial. From the DAG extracts,
methyl esters were prepared by transmethylation using a
mixture of toluene-methanol-(BF3-methanol 14%)
(20–55–25% by volume) at 100C for 30 min. The fatty
acid methyl esters were separated by capillary gas liquid
chromatography using a 50 m 9 0.25 mm CP-sil 88 silica
column (Varian) with helium as carrier gas at a ﬂow of
130 kPa. Fatty acids were identiﬁed by comparison with a
standard mixture of fatty acid methyl esters.
Alternatively, cells were pre-incubated for 16 h with
[1-
14C] palmitate (0.5 lCi/ml; PerkinElmer, Boston, MA,
USA) and respective non-labeled (cold) palmitate
(100 lM). Following incubation, cells were washed twice
with 19 PBS and harvested into 0.25 ml of 0.05% SDS for
subsequent protein measurement and total lipid extraction
with 1 ml of chloroform/methanol (2v/1v). Lipids were
washed with 70% ethanol and re-dissolved for thin layer
chromatography (TLC) (Anal Tech TLC plates; Whatman,
Kent, ME, USA) and run in a mobile phase containing
hexane/diethyl ether/acetic acid, v/v/v, 80:20:1). Bands
corresponding diacylglycerol (DAG) were scraped and
transferred into scintillation vials, and radioactivity was
measured on a multipurpose scintillation counter (LS 6500;
Beckman Coulter, Brea, CA, USA). All assays were per-
formed in triplicate, and data were normalized to protein
content.
Transfections and plasmids
Stable celllines werecreatedbytransfectionwith Nanofectin
(PAA) according to manufacturers’ recommendations.
To inhibit NF-jB activation, L6 myoblasts (3 9 10
3
cells/cm
2) were stably transfected with nanofectin in the
presence of a plasmid encoding IjBa-SR (3 lg), which was
constitutively expressed under control of the SFFV-LTR
(pSFFV-NEO IjBa-SR), kindly provided by Dr. Rosa Ten
(Mayo Clinic, Rochester, MN, USA). A control cell line
was created using the same strategy, with plasmid DNA
containing the neomycin resistance gene (pSV2-Neo;
Stratagene, La Jolla, CA, USA). For selection of positive
clones, cells were cultured in GM containing the presence
of 800 lg/ml G-418 (Calbiochem).
NF-jB transcriptional activity
To determine NF-jB transcriptional activity, luciferase
activity was measured in a NF-jB sensitive reporter cell
line as previously described [28]. After the appropriate
incubation time with the various stimuli, cells were washed
twice with cold phosphate-buffered salin (PBS) and lysed
by adding 100 ll1 9 Reporter Lysis Buffer (Promega,
Madison, WI, USA). After incubation on ice for 10 min,
cell lysates were centrifuged (13,000g, 2 min) and stored at
-80C until analysis. Luciferase activity was measured
according to the manufacturers’ instructions (Promega) and
corrected for total protein content (Bio-Rad, Hercules, CA,
USA).
Electrophoretic mobility shift analysis
To determine DNA binding activity of NF-jB, complexes
binding to an oligonucleotide containing a NF-jB con-
sensus sequence were analyzed by EMSA. Nuclear extracts
were isolated to analyze NF-jB DNA binding. To this end,
cells were harvested following experimental treatments and
lysed on ice in 400 ll buffer containing 20 mmol/l HEPES,
pH 7.8, 20 mmol/l KCl, 4 mmol/l MgCl2, 0.2 mmol/l
EDTA, 1 mmol/l DTT, 0.2 mmol/l sodiumorthovanadate,
0.4 mmol/l phenylmethyl sulfonylﬂuoride, 0.3 lg/ml leu-
peptin and 0.2 mmol/l NaF for 15 min. Subsequently, 25 ll
10% Nonidet P40 was added and samples were vortexed
for 15 s followed by centrifugation (14,000g for 30 s).
Supernatants were removed and pelleted nuclei were
washed with the previously mentioned buffers and resus-
pended with a buffer containing 100 mmol/l HEPES, pH
7.8, 100 mmol/l KCl, 600 mmol/l NaCl, 0.2 mmol/l
EDTA, 20% glycerol, 1 mmol/l DTT, 0.2 mmol/l
sodiumorthovanadate, 0.667 mmol/l phenylmethyl sulfo-
nylﬂuoride and 0.2 mmol/l NaF. Nuclei were mixed
vigorously for 20 min at 4C using a rotating platform,
centrifuged (14,000g for 5 min) and samples were stored at
-20C (for protein concentration determination) and
-80C (for DNA binding activity measurements). 7 lg
nuclear cell extracts were used per binding reaction, and
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acrylamide gel in 0.25 9 Tris borate-EDTA buffer
at 160 V for 2 h. Gels were dried and exposed to ﬁlm
(X-Omat Blue XB-1; Kodak, Rochester, NY, USA). Shifted
complexes were quantiﬁed by phosphoimager analysis
(Bio-Rad). To determine the presence of RelA (p65) by
supershift analysis, nuclear extracts were pre-incubated
with an antibody speciﬁc to the RelA subunit of NF-jB
(Santa Cruz Biotechnology).
[
3H]deoxyglucose uptake
Basal and insulin-dependent deoxyglucose uptake was
determined as described previously [12]. In brief, L6
myotubes with or without FA preincubation were serum
deprived for 3 h prior to incubation with 25 nmol/l insulin
(Sigma) for 15 min at 37C in glucose-free medium. Label
(0.2 lCi/ml [
3H]deoxyglucose) was added (ﬁnal concen-
tration of 20 lmol/l) and incubated for 20 min at 37C.
Glucose transport was terminated by washing three times
with an ice-cold stop-solution containing 0.2 mmol/l
phloretin and cells were harvested in 0.5 ml 0.05 mol/l
NaOH. Cell-associated radioactivity was determined by
scintillation counting.
Statistical analysis
SPSS (version 16.0) was used for statistical analysis. Data
were analyzed by one-way ANOVA, and the various
treatment groups were compared by using the post-hoc
Bonferroni test in which a P\0.05 was considered sta-
tistically signiﬁcant. Data is presented as means ± SD.
Data shown are representative examples of three indepen-
dent experiments.
Results
Palmitate induces insulin resistance, DAG
accumulation and NF-jB activation in myotubes
Verifying previous ﬁndings considering palmitate-induced
insulin resistance, L6 myotubes were treated for 16 h with
200 lmol/l palmitate. As expected, incubation with pal-
mitate suppressed insulin-stimulated deoxyglucose uptake
compared with untreated cells (Fig. 1a). This palmitate-
induced insulin resistance coincided with a ﬁvefold
increase in diacylglycerol (DAG) accumulation (Fig. 1b).
To determine the effects of palmitate incubation on NF-jB
Fig. 1 Palmitate induces insulin resistance, DAG accumulation and
NF-jB transactivation in myotubes. a L6 myoblasts were differen-
tiated for 5 days and subsequently incubated for 16 h with and
without 200 lmol/l palmitate prior to stimulation with 25 nmol/l
insulin for 15 min (white bars no insulin stimulation; black bars
insulin stimulation). 2-deoxyglucose uptake was measured as
described in ‘‘Materials and methods’’, and insulin-stimulated glucose
uptake was expressed as fold induction over basal (non-insulin
stimulated) glucose uptake. *P\0.05. Alternatively, L6 myotubes
were incubated with 200 lmol/l palmitate for 16 h, after which
b DAG accumulation was determined by thin layer chromatography,
corrected for protein content and expressed as fold change to control,
or c NF-jB DNA binding was determined by EMSA, as described in
‘‘Materials and methods’’ and expressed as fold induction over
control. *P\0.05. d Alternatively, C2C12 myoblasts stably trans-
fected with the 6jB-TK-luciferase construct were differentiated for
5 days and incubated with 400 lmol/l of palmitate for 24 h. Lysates
were prepared for assessment of luciferase activity. Values were
corrected for protein content and expressed as fold-induction over
control. *P\0.05
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myotubes. Palmitate treatment resulted in a *3.2-fold
increase in DNA binding (Fig. 1c). To test whether the
increased DNA binding led to an increased NF-jB trans-
activation, we measured transcriptional activity in C2C12
myotubes, stably transfected with a NF-jB sensitive
reporter construct. Palmitate increased NF-jB dependent
luciferase activity (Fig. 1d), which conﬁrmed the DNA
binding results in L6 myotubes.
Blocking b-oxidation sensitizes myotubes
to palmitate-induced insulin resistance
and NF-jB transactivation
Impaired FA oxidation causes lipid accumulation in
skeletal muscle [29]. To assess the effects of intramyo-
cellular lipid (IMCL) accumulation on insulin sensitivity
and NF-jB activity, FA-oxidation was inhibited by
blocking carnitine palmitoyltransferase-1 (CPT-1), an
enzyme mediating the transport of long chain fatty acids
across the mitochondrial membrane. Myotubes were
incubated with 80 lmol/l etomoxir, an irreversible inhib-
itor of CPT-1 [30]. Supplementary Fig. 1 demonstrates
that this concentration of etomoxir resulted in a *twofold
increase in DAG accumulation in presence of 100 lmol/l
palmitate. Treatment of etomoxir without additional FA
had no effects on insulin-induced glucose uptake (Fig. 2a).
Also treatment of myotubes with the low concentration of
100 lmol/l palmitate alone had no effects on insulin
sensitivity, while increasing the palmitate concentrations
resulted as expected in a reduced insulin-induced glucose
uptake. In contrast, co-incubation of palmitate and etom-
oxir already reduced insulin-stimulated glucose uptake at
100 lmol/l palmitate. Moreover, inhibition of b-oxidation,
inducing DAG accumulation, further enhanced the
insulin resistance induced by increasing palmitate
concentrations.
To investigate if sensitization to palmitate-induced
insulin resistance by etomoxir coincided with enhanced
NF-jB activation, we determined the effect of co-incuba-
tion of etomoxir and palmitate on NF-jB transcriptional
activity (Fig. 2b). Again, etomoxir and 100 lmol/l palmi-
tate alone had no effect compared to control, while co-
incubation with these two agents simultaneously resulted in
an increased NF-jB transcriptional activity. Palmitate
increased NF-jB transcriptional activity in a dose-respon-
sive manner, whereas etomoxir had a synergistic effect, as
it further enhanced (an additional 1.4–1.8 fold) palmitate-
induced NF-jB activation. These data reveal that inhibition
of b-oxidation sensitizes myotubes to palmitate-induced
NF-jB activation and insulin resistance, and suggest that
NF-jB activation and insulin resistance are coupled under
conditions of DAG accumulation.
Segregation of palmitate-induced NF-jB
transactivation and insulin resistance following
inhibition of DAG conversion
Diacylglycerol acyltransferase (DGAT) is an enzyme
involved in the formation of triglycerides from diacyl-
glycerol (DAG) and acyl-coA in insulin-sensitive tissues
like skeletal muscle. In a second approach to study the
effects of DAG accumulation on NF-jB activation and
insulin resistance, we used the DGAT inhibitor amidepsine
[31]. Amidepsine signiﬁcantly increased DAG
Fig. 2 Blocking b-oxidation sensitizes myotubes to palmitate-
induced insulin resistance and NF-jB transactivation. a L6 myotubes
were treated for 16 h with the indicated palmitate concentrations in
presence (gray bars) or absence (white bars) of etomoxir prior to
insulin stimulation (open bars no insulin stimulation; hatched bars
insulin stimulation). 2-deoxyglucose uptake was measured as
described in ‘‘Materials and methods’’, and insulin-stimulated glucose
uptake was expressed as fold induction over basal (non-insulin
stimulated) glucose uptake. *P\0.05 versus insulin-stimulated cells
without palmitate treatment.
#P\0.05 versus insulin-stimulated cells
with the same palmitate treatment. b C2C12 myoblasts stably
transfected with the 6jB-TK-luciferase reporter construct were
differentiated for 5 days and incubated with indicated palmitate
concentrations for 24 h. Cells were co-incubated with (gray bars) and
without (white bars) etomoxir. Lysates were prepared for assessment
of luciferase activity. Values were corrected for protein content and
expressed as fold-induction over control. *P\0.05 versus control
cells without palmitate treatment.
#P\0.05 versus non-etomoxir
treated cells with the same palmitate treatment
Insulin resistance is independent of NF-jB 1219accumulation (supplementary Fig. 1) in L6 myotubes.
Treatment of myotubes with 10 lg/ml (*8.8 lmol/l)
amidepsine in absence of palmitate did not affect insulin-
induced glucose uptake (Fig. 3a). However, in line with
the effects of etomoxir treatment, amidepsine sensitized
myotubes to palmitate-induced insulin resistance, and co-
incubation of 150 lmol/l palmitate with amidepsine already
completely abolished insulin-mediated glucose uptake.
In contrast to the effects of etomoxir, amidepsine
treatment did not further increase, but even slightly
reduced palmitate-induced NF-jB transcriptional activity
(Fig. 3b), despite a signiﬁcant increase (38% compared to
palmitate without amidepsine, P = 0.004) in C2C12
myotubes. These ﬁndings reveal segregation of palmitate-
induced DAG accumulation, insulin resistance and NF-jB
activation following inhibition of DAG conversion, and
suggest that NF-jB may not be required for palmitate-
induced insulin resistance.
Pharmacological or genetic inhibition of NF-jB does
not prevent palmitate-induced insulin resistance
in myotubes
To test whether the NF-jB pathway is causally linked to
palmitate-induced insulin resistance, pharmacological and
genetic approaches were employed to inhibit NF-jB. First,
C2C12 myotubes were incubated with 20 lmol/l parthe-
nolide, an agent that inhibits NF-jB activation by
inhibiting IKK activity [32]. The NF-jB inhibitory
capacity of parthenolide was conﬁrmed as it blocked
TNFa-induced NF-jB activity in myotubes (data not
shown). Parthenolide resulted in a complete abolishment of
palmitate-induced NF-jB transcriptional activity (Fig. 4a).
In spite of this potent NF-jB inhibitory capacity, the pal-
mitate-induced reduction of glucose uptake could not be
prevented by parthenolide (Fig. 4b), which—in line with
the amidepsine ﬁndings—suggests that palmitate-induced
NF-jB activation and insulin resistance are not causally
related.
To further conﬁrm these ﬁndings, we also inhibited the
NF-jB pathway by genetic modiﬁcation, using IjBa-SR, a
non-degradable mutant of IjBa. As expected, increased
NF-jB DNA binding after treatment with palmitate
(Fig. 5a) or TNFa (data not shown) was not observed in L6
cells expressing the IjBa-super repressor (SR), in contrast
to control myotubes. In complete accordance with the
parthenolide results, there was no improvement in insulin-
induced glucose uptake in IjBa-SR myotubes treated with
palmitate (Fig. 5b). Thus, neither pharmacological and
genetic blockade of NF-jB could prevent palmitate-
induced insulin resistance in skeletal muscle cells, illus-
trating NF-jB activity in skeletal muscle is not required for
palmitate-induced insulin resistance.
Discussion
Lipid infusion-induced insulin resistance in human skeletal
muscle is asscociated with an increase in diacylglycerol
(DAG) mass and a reduction in IjBa protein levels [8].
This led to the suggestion that DAG accumulation, NF-jB
activation and insulin resistance are causally related. Here,
we show that palmitate-induced insulin resistance in
Fig. 3 Segregation of palmitate-induced NF-jB transactivation and
insulin resistance following inhibition of DAG conversion. a L6
myotubes were treated for 16 h with the indicated palmitate
concentrations in presence (gray bars) or absence (white bars)o f
amidepsine A prior to insulin stimulation (open bars no insulin
stimulation; hatched bars insulin stimulation). 2-deoxyglucose uptake
was measured as described in ‘‘Materials and methods’’, and insulin-
stimulated glucose uptake was expressed as fold induction over basal
(non-insulin stimulated) glucose uptake. *P\0.05 versus insulin-
stimulated cells without palmitate treatment.
#P\0.05 versus
insulin-stimulated cells with the same palmitate treatment. b C2C12
myoblasts stably transfected with the 6jB-TK-luciferase reporter
construct were differentiated for 5 days and incubated with indicated
palmitate concentrations for 24 h. Cells were co-incubated with (gray
bars) and without (white bars) amidepsine A. Lysates were prepared
for assessment of luciferase activity. Values were corrected for
protein content and expressed as fold-induction over control.
*P\0.05 versus control cells without palmitate treatment.
#P\0.05 versus non-amidepsine A treated cells with the same
palmitate treatment
1220 P. P. H. Hommelberg et al.skeletal muscle cells indeed coincides with increased NF-
jB activation and DAG accumulation.
However,ourintramyocellularlipidmetabolitemodulating
experimentsuncoupledtheeffectsofpalmitate-inducedDAG
accumulation and insulin resistance from NF-jBa c t i v a t i o n .
Furthermore, pharmacological and genetic inhibition of the
NF-jB pathway could not prevent the palmitate-induced
reduction in insulin-stimulated glucose uptake. Altogether,
this implies that NF-jB activation is not a causal factor in
palmitate-induced insulin resistance in skeletal muscle.
FA oversupply results in increased intra-myocellular lipid
(IMCL) and consequent lipid metabolite accumulation, and
this was reproduced by pharmacological inhibition of carni-
tine palmitoyltransferase 1 (CPT-1) using etomoxir. By
irreversible inhibition of CPT-1, etomoxir is able to block the
entry of long-chain fatty acyl-CoA into mitochondria [30, 33,
34]. Consequently, CPT-1 inhibition results in intramyocel-
lular lipid (IMCL) accumulation [29] and may therefore lead
to cytoplasmatic accumulation of lipid metabolites, like pal-
mitoyl-CoA, DAG and ceramide, which have all been
implicated inthe pathogenesis ofinsulin resistancein skeletal
muscle [8, 11, 35–39]. Indeed, treatment with etomoxir sen-
sitized myotubes to palmitate-induced DAG accumulation
and insulin resistance, causing decreased insulin-stimulated
glucose uptake even with non-insulin resistance-inducing
palmitateconcentrations.Theseresultsareinagreementwitha
study in rats, where inhibition of CPT-1 by prolonged etom-
oxiradministrationresultedinincreasedIMCLaccumulation,
associated with insulin resistance [29]. Furthermore, CPT-1
over-expression in L6E9 muscle cells prevented DAG and
ceramide accumulation and activation of protein kinase C
(PKC)-h and –f after palmitate incubation, and resulted in
protection from palmitate-induced insulin resistance [40].
Fig. 4 Pharmacological inhibition of NF-jB does not prevent
palmitate-induced insulin resistance in myotubes a C2C12 myoblasts
stably transfected with the 6jB-TK-luciferase construct were differ-
entiated for 5 days and incubated with 400 lmol/l palmitate and 20
lmol/l parthenolide for 24 h as indicated. Lysates were prepared for
assessment of luciferase activity. Values were corrected for protein
content and expressed as fold-induction over control. *P\0.05
versus control.
#P\0.05 versus non-parthenolide palmitate-treated
cells. b L6 myotubes were treated for 16 h with 200 lmol/l palmitate
in presence or absence of 20 lmol/l parthenolide prior to insulin
stimulation (open bars no insulin stimulation; black bars insulin
stimulation). 2-deoxyglucose uptake was measured as described in
‘‘Materials and methods’’, and insulin-stimulated glucose uptake was
expressed as fold induction over basal (non-insulin stimulated)
glucose uptake. *P\0.05 versus control.
#P\0.05 versus insulin-
stimulated control
Fig. 5 Genetic inhibition of NF-jB does not prevent palmitate-
induced insulin resistance in myotubes Stably transfected L6 cells,
carrying a plasmid encoding a stabilized mutant of the Inhibitor of
NF-jB( I jBa-SR) or an empty vector (e.v.), were differentiated for
5 days and cultured for 16 h in presence or absence of 200 lmol/l
palmitate. a Nuclear extracts were prepared and assessed for DNA
binding activity to a consensus NF-jB oligonucleotide by EMSA.
b Control- or IjBa-SR-myotubes were treated for 16 h with 200
lmol/l palmitate prior to insulin stimulation (open bars no insulin
stimulation; black bars insulin stimulation). 2-deoxyglucose uptake
was measured as described in ‘‘Materials and methods’’, and insulin-
stimulated glucose uptake was expressed as fold induction over own
basal (non-insulin stimulated) glucose uptake. *P\0.05 versus
control
Insulin resistance is independent of NF-jB 1221Another approach to manipulate accumulation of lipid
metabolites is by inhibiting diacylglycerol acyltransferase
(DGAT), the enzyme facilitating binding of DAG to long-
chain acyl-CoAs to form triacylglycerol (TAG), using ami-
depsine A [31, 41]. In accordance with the etomoxir results,
we found that inhibiting DGAT by amidepsine A resulted in
DAG accumulation and sensitized myotubes to palmitate-
inducedinsulinresistance.Inlinewiththis,over-expressionof
DGAT1 in skeletal muscle of mice resulted in protection
against high fat diet-induced insulin resistance, which coin-
cidedwithdecreasedDAGandceramidelevelsandincreased
TAG levels [42]. This was associated with attenuated fat-
induced activation of JNK and DAG-responsive PKCs. Fur-
thermore, the same authors showed that, in isolated soleus
muscle from DGAT knockout mice, the insulin-induced
reduction in glucose uptake after administration of a palmi-
tate/oleate mixture is exacerbated compared to wild-type
muscle, which coincided with increased DAG and ceramide
levels.Conversely,musclesover-expressingDGAT1showed
enhanced insulin sensitivity, associated with decreased DAG
and ceramide levels (comparable to muscle from wild-type
mice) [42]. Whether DAG or ceramides are responsible for
palmitate-induced insulin resistance cannot be concluded
from our experiments, since accumulation of palmitoyl-CoA
might not only lead to the formation of DAG, but also to
ceramides.Sincepalmitoyl-CoAisaprecursorinsphingolipid
synthesis [43], etomoxir or amidepsine treatment may lead to
enhanced ceramide synthesis, as has been reported for etom-
oxir in hematopoietic cell lines [44].
While etomoxir alone did not induce NF-jB activation, it
did increase NF-jB transactivation when co-incubated with
100 lmol/l palmitate. However, in contrast to etomoxir,
direct interference with DAG metabolism by inhibiting the
conversion from DAG to TAG with amidepsine did not
increasepalmitate-inducedNF-jBtransactivation.Basedon
these results, it is unlikely that DAG or DAG-induced PKC
activation is responsible for NF-jB activation as DAG
accumulationwasobservedinresponsetobothetomoxirand
amidepsine. Ceramides are known activators of NF-jB
[45, 46] and are therefore a likely candidate for the observed
NF-jB activation in response to palmitate.
Moreover, these differential effects of lipid metabolite
modulation on insulin resistance and NF-jB activation
suggest that FA-induced insulin resistance and NF-jB
activation in skeletal muscle are not related. This dissoci-
ation between FA-induced NF-jB activity and insulin
resistance was also postulated in a recent study from our
group [23], in which we showed that several unsaturated
fatty acids were able to increase NF-jB DNA binding and
transcriptional activity in myotubes without inducing
insulin resistance, which further supports that fatty acid-
induced insulin resistance and NF-jB activation in muscle
may occur independently.
Several studies in rodents and humans show that fat-
induced insulin resistance is associated with NF-jB acti-
vation in skeletal muscle [8, 15, 16]. Although previous
associations between palmitate-induced insulin resistance
and NF-jB activation in skeletal muscle cells have also
been reported [12, 14], we now show by pharmacological
and by genetic inhibition that a causal relationship between
both processes can be ruled out.
Previous studies investigating this potential association
used inhibition of IKK by high doses of salicylate or by
heterozygous deletion, which prevented lipid infusion-,
obesity- and diet-induced insulin resistance in skeletal
muscle [17, 18]. However, it has been shown that salicylate
may reverse TNF-a-induced insulin resistance indepen-
dently of IKK-2/NF-jB inhibition [47]. In this study,
salicylate inhibited JNK activation, and the latter has also
implicated in obesity-induced insulin resistance [48]. Fur-
thermore, there is evidence from several in vivo studies
that the NF-jB pathway in skeletal muscle is not required
for high-fat diet-induced insulin resistance. Muscle-speciﬁc
inhibition of NF-jB by transgenic expression of the IjBa
super-repressor (MISR mice) did not protect against the
development of obesity-induced insulin resistance, fol-
lowing a high fat diet for 3 months [19]. Muscle-speciﬁc
IKK-2-deﬁcient mice were not protected against whole
body or muscle insulin resistance induced by gold thio-
glucose or high-fat [20]. Taken together, these in vivo
studies suggest that activation of the NF-jB pathway in
muscle does not seem to play a causal role in high-fat-
induced insulin resistance.
In fact, the evidence causally relating FA-induced
insulin resistance in muscle to NF-jB activation is entirely
derived from in vitro studies using L6 skeletal muscle cells
[21], in which it was shown that pharmacological inhibition
of IKK (using parthenolide and acetylsalicylate) or block-
ade of nuclear translocation of NF-jB prevented palmitate-
induced reductions in insulin-stimulated glucose uptake.
The acetylsalicylate-induced effects on insulin resistance
may be IKK independent, since it is known that acetylsa-
licylate blocks several kinases, including JNK, [49], which
as pointed out above has been implicated in insulin resis-
tance. In addition, SN50, a peptide used to block nuclear
import of NF-jB[ 50], was used as proof that nuclear
translocation of NF-jB is required for the insulin-desen-
sitizing effects of palmitate [21]. However, these data
should be interpreted with care as SN50 displays inhibitory
activity towards the nuclear translocation of a range of
transcription factors other than NF-jB[ 51]. Importantly,
SN50 also blocks nuclear import of activator protein (AP)-
1, which is a JNK-responsive transcription factor, sug-
gesting that reversal of insulin resistance by SN50 can also
be explained by inhibition of the JNK/AP-1 pathway which
has been implicated in insulin resistance [48].
1222 P. P. H. Hommelberg et al.In contrast to the observations concerning reversal of
insulin sensitivity following NF-jB inhibition by parthe-
nolide [21], in our hands parthenolide, despite complete
ablation of NF-jB activation, displayed no protection
against palmitate-induced insulin resistance. Although it is
difﬁcult to reconcile these opposing ﬁndings, we are
conﬁdent of our data as a second, genetic approach to
inhibit NF-jB yielded identical results. Here, we showed
that complete ablation of NF-jB activation by IjBa-SR in
L6 cells did not prevent palmitate-induced insulin resis-
tance. A similar strategy to inhibit muscular NF-jB
activation also ruled out a role of muscle NF-jB in high-
fat-induced insulin resistance [19]. Although insulin
resistance of other tissues could potentially have masked a
protective effect of NF-jB inhibition in muscle as whole
body insulin sensitivity was measured in that study, our
ﬁndings further extend the evidence against an important
role for NF-jB in skeletal muscle insulin resistance as
insulin sensitivity was measured directly in cultured
muscle. Finally, in line with previous reports [24–26],
LPS and TNF-a were not able to induce insulin resistance
in myotubes despite potent NF-jB activation (data not
shown). This further conﬁrms ﬁndings that muscle-spe-
ciﬁc NF-jB activation is not sufﬁcient to induce insulin
resistance [19, 52], and underlines the notion that NF-jB
activation and insulin resistance in skeletal muscle are not
causally related.
In conclusion, we demonstrate that manipulation of
DAG accumulation by inhibiting DGAT or b-oxidation
resulted in segregation of palmitate-induced insulin resis-
tance and NF-jB activation, suggesting that these
processes are not related. By pharmacological and genetic
inhibition of the NF-jB pathway, we reveal that activation
of the NF-jB pathway is not required for palmitate-
induced insulin resistance in skeletal muscle cells.
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